Publications

Brandt SJ, Muller TD, DiMarchi RD, Tschop MH, Stemmer K (2018) Peptide-based multi-agonists: a new paradigm in metabolic pharmacology. J Intern Med 284 (6):581-602.
doi:10.1111/joim.12837


Kabacaoglu D, Ciecielski KJ, Ruess DA, Algul H (2018) Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Front Immunol 9:1878.
doi:10.3389/fimmu.2018.01878


Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombroswki F, Weiss FU, Neoptolemos JP, Werner J, D'Haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Buchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J (2018) Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology 155 (5):1625-1639 e1622.
doi:10.1053/j.gastro.2018.08.009


Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC (2018) Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discov 8 (11):1458-1473.
doi:10.1158/2159-8290.CD-18-0046